Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: A population-based controlled cohort study

Annals of the Rheumatic Diseases

Volumn 69, Issue 12, 2010, Pages 2131-2136

  Olofsson, Tor ^a   Englund, Martin ^a,b   Saxne, Tore ^a   Jöud, Anna ^a   Jacobsson, Lennart T H ^c   Geborek, Pierre ^a   Allaire, Saralynn ^b   Petersson, Ingemar F ^a  

^a LUND UNIVERSITY   (Sweden)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; SWEDEN; WORK DISABILITY;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; SICK LEAVE; SWEDEN; TUMOR NECROSIS FACTOR-ALPHA; WORK CAPACITY EVALUATION; YOUNG ADULT;

EID: 78649758316     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.127852     Document Type: Article

References (35)

1. Allaire S, Wolfe F, Niu J, et al. Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum 2008;59:474-80. (Pubitemid 351563528)
2. Verstappen SM, Bijlsma JW, Verkleij H, et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004;51:488-97.
3. Burton W, Morrison A, Maclean R, et al. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) 2006;56:18-27.
4. Jäntti J, Aho K, Kaarela K, et al. Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20 year study. Rheumatology (Oxford) 1999;38:1138-41.
5. Kobelt G. Health economic issues in rheumatoid arthritis. Scand J Rheumatol 2006;35:415-25.
6. Puolakka K, Kautiainen H, Möttönen T, et al. Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum Dis 2005;64:130-3.
7. Hallert E, Husberg M, Jonsson D, et al. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology (Oxford) 2004;43:1374-82.
8. Emery P, Kvien TK. Treating rheumatoid arthritis. BMJ 2007;335:56-7.
9. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
10. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
11. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
12. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45. (Pubitemid 36091645)
13. Landewé R, van der Heijde D, Klareskog L, et al. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119-25.
14. Gülfe A, Kristensen LE, Saxne T, et al. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden. Ann Rheum Dis 2010;69:352-7.
15. Augustsson J, Neovius M, Cullinane-Carli C, et al. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis 2010;69:126-31.
16. Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59:1467-74.
17. Halpern MT, Cifaldi MA, Kvien TK. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group. Ann Rheum Dis 2009;68:930-7.
18. Smolen JS, Han C, van der Heijde D, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:716-22.
19. Mittendorf T, Dietz B, Sterz R, et al. Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Rheumatology (Oxford) 2008;47:188-93.
20. Allaire S, Wolfe F, Niu J, et al. Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum 2008;59:1082-9.
21. Laas K, Peltomaa R, Kautiainen H, et al. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment. Ann Rheum Dis 2006;65:924-8.
22. Strömbeck B, Jacobsson LT, Bremander A, et al. Patients with ankylosing spondylitis have increased sick leave-a registry-based case-control study over 7 yrs. Rheumatology (Oxford) 2009;48:289-92.
23. Geborek P, Saxne T. Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis. Rheumatology 2000;39:1159-61.
24. Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
25. Geborek P, Nitelius E, Noltorp S, et al. Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales. Ann Rheum Dis 2005;64:1805-7.
26. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
27. Baecklund E, Bokarewa M, Turesson C. Guidelines for treatment of RA patients. Swedish Society for Rheumatology. http://www.svenskreumatologi.se/ (accessed 10 July 2010).
28. Altman DG. Practical statistics for medical research. London, UK: Chapman & Hall, 1991. Reprint 1999 by CRC Press LCC:230, 266-8.
29. Puolakka K, Kautiainen H, Pekurinen M, et al. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis 2006;65:899-904.
30. Lidwall U. National official statistics on disability pension. http://statistik.forsakringskassan.se/ (accessed 10 July 2010).
31. Lidwall U. 2010. National official statistics on sick leave. http://statistik.forsakringskassan.se/ (accessed 10 July 2010).
32. Eberhardt K, Larsson BM, Nived K, et al. Work disability in rheumatoid arthritis-development over 15 years and evaluation of predictive factors over time. J Rheumatol 2007;34:481-7.
33. Sokka T, Toloza S, Cutolo M, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 2009;11:R7.
34. Lard LR, Huizinga TW, Hazes JM, et al. Delayed referral of female patients with rheumatoid arthritis. J Rheumatol 2001;28:2190-2.
35. Hawker GA, Wright JG, Coyte PC, et al. Differences between men and women in the rate of use of hip and knee arthroplasty. N Engl J Med 2000;342:1016-22.